145 completed, 19 terminated, 19 unknown, 16 recruiting. 219 Phase 1, 46 Phase 2.
Follow Hepatitis B: new trials by email Literature Review of Hepatitis B trials Research Report on Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants Bepirovirsen - Hepatitis B | Phase 1 | Not yet recruiting | GlaxoSmithKline | 98 | 2026-11-03 | 2026-10-29 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, Placebo, TVAX-008 - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 105 | 2026-10-31 | 2026-10-19 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B ACT500 Tablets, ACT500 Placebo Tablets - Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | 24 | 2026-10-30 | 2026-09-14 |
| A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants AHB-121, Placebo - Chronic Hepatitis B Virus | Phase 1 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 110 | 2026-10-28 | 2026-10-21 |
| Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B SCTA02A, Placebo - Hepatitis B | Phase 1 | Not yet recruiting | Sinocelltech Ltd. | 60 | 2026-10-01 | 2026-10-29 |
| A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection WGc0201 - Chronic Hepatitis B Virus (Hbv) | Phase 1 | Recruiting | Jiyan Liu | 9 | 2026-09-01 | 2026-07-01 |
| A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function. AHB-137 injection - Chronic Hepatitis B | Phase 1 | Recruiting | Ausper Biopharma Co., Ltd. | 32 | 2026-07-09 | 2026-07-29 |
| Study of AHB-171 in Chronic Hepatitis B Participants AHB-171, Placebo matching [Investigational Product], Nucleos(t)ide Analogue (NA) - Hepatitis B, Chronic | Phase 1 | Not yet recruiting | AusperBio Therapeutics Inc. | 144 | 2026-07-06 | 2026-06-01 |
| A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B. CPU-YL01 Injection Intramuscular administration, Placebo intramuscular injection - Chronic Hepatitis B | Phase 1 | Enrolling by invitation | Jiangsu Chuangyuan Life Science and Technology Co., Ltd. | 74 | 2026-07-03 | 2026-11-05 |
| A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants AHB-171 Injection, Placebo, Nucleos(t)ide Analogue (NA) - Chronic Hepatitis B Infection | Phase 1 | Recruiting | Ausper Biopharma Co., Ltd. | 110 | 2026-04-13 | 2026-07-21 |
| Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function Pevifoscorvir Sodium (ALG-000184) - Chronic Hepatitis B Infection | Phase 1 | Completed | Aligos Therapeutics | 12 | 2026-03-10 | 2026-08-21 |
| A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Therapeutic hepatitis B vaccine, Commercial Hepatitis B vaccine - Chronic Hepatitis b | Phase 1 / Phase 2 | Not yet recruiting | Vaxine Pty Ltd | 40 | 2026-03-01 | 2025-09-22 |
| A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B IB-001, Placebo, Peginterferon Alfa-2A - Chronic Hepatitis B Virus Infection | Phase 1 | Recruiting | IntegerBio | 88 | 2026-02-20 | 2026-09-28 |
| A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B CRMA-1001 - Chronic Hepaititis B | Phase 1 / Phase 2 | Recruiting | nChroma Bio | 66 | 2025-12-22 | 2026-06-15 |
| SA1211 Injection Phase 1 Study SA1211 injection, SA1211 injection placebo - Chronic Hepatitis B | Phase 1 | Recruiting | Suzhou Siran Biotechnology Co.,Ltd. | 80 | 2025-11-25 | 2025-12-10 |
| TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B] - Hepatitis B, Chronic Hepatitis B | Phase 1 | Recruiting | University of Maryland, Baltimore | 10 | 2025-10-16 | 2025-10-20 |
| A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease Bepirovirsen - Hepatitis B | Phase 1 | Active not recruiting | GlaxoSmithKline | 32 | 2025-09-26 | 2026-05-22 |
| A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults SN2001 - Chronic Hepatitis B Infection | Phase 1 | Active not recruiting | Chimivac INC | 36 | 2025-08-19 | 2026-10-13 |
| TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac), TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac) - Chronic Hepatitis B | Phase 1 / Phase 2 | Recruiting | Michael Hoelscher | 81 | 2025-06-12 | 2026-06-11 |
Showing 20 of 219. Sign in to see all of them.
Hepatitis B, Chronic (146) · Hepatitis (8) · Liver Diseases (7) · Hepatitis C (5) · Virus Diseases (5) · Bronchiolitis Obliterans Syndrome (4) · Carcinoma, Hepatocellular (4) · Hepatitis, Chronic (4) · Communicable Diseases (3) · DNA Virus Infections (2) · Diphtheria (2) · Fibrosis (2) · HIV Infections (2) · Haemophilus Infections (2)
Blood-Borne Infections (219) · Digestive System Diseases (219) · Hepadnaviridae Infections (219) · Hepatitis, Viral, Human (219) · DNA Virus Infections (217) · Infections (217) · Communicable Diseases (216) · Virus Diseases (214) · Liver Diseases (212) · Hepatitis (211) · Pathologic Processes (154) · Pathological Conditions, Signs and Symptoms (154) · Disease Attributes (151) · Chronic Disease (147) · Hepatitis, Chronic (142)
entecavir (22) · Tenofovir (17) · peginterferon alfa-2a (14) · Hepatitis B Vaccines (6) · tenofovir alafenamide (5) · Engerix-B (4) · Heplisav-B (4) · Drug and Narcotic Control (3) · Midazolam (3) · NVR 3-778 (3) · Telbivudine (3) · adefovir dipivoxil (3) · mycophenolic adenine dinucleotide (3) · Aluminum Hydroxide (2) · Itraconazole (2)
GlaxoSmithKline (13) · Assembly Biosciences (10) · Hoffmann-La Roche (9) · Gilead Sciences (6) · Aligos Therapeutics (5) · Ausper Biopharma Co., Ltd. (5) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (5) · Dynavax Technologies Corporation (4) · Enanta Pharmaceuticals, Inc (4) · Sunshine Lake Pharma Co., Ltd. (4) · Alios Biopharma Inc. (3) · Beijing 302 Hospital (3) · Bristol-Myers Squibb (3) · Chong Kun Dang Pharmaceutical (3) · Enyo Pharma (3)
China (65) · New Zealand (48) · United States (45) · South Korea (35) · Hong Kong (33) · Australia (25) · Taiwan (24) · United Kingdom (24) · Thailand (15) · Belgium (12) · France (12) · Moldova (12) · Singapore (12) · Germany (11) · Canada (10)
Benedetta Massetto, M.D. (2) · Guiqiang Wang (2) · Junqi Niu (2) · Junqi Niu, PHD (2) · Mamun Al-Mahtab, MD (2) · Yan Wang (2)
PMID 27257978, PMID 30625297, PMID 37290591, PMID 42550463, PMID 1538192, PMID 15577929, PMID 16310901, PMID 16375711, PMID 20090916, PMID 20091678, PMID 22981147, PMID 23774433, PMID 23941866, PMID 24148552, PMID 24394187, PMID 24555998, PMID 24995515, PMID 25406369, PMID 25426834, PMID 28737510, PMID 29660190, PMID 30088198, PMID 30711630, PMID 30863450, PMID 31323705, PMID 31711752, PMID 32049318, PMID 32839221, PMID 32912268, PMID 32928858, PMID 34037271, PMID 34237271, PMID 34280012, PMID 34562067, PMID 34741731, PMID 35040959, PMID 35404074, PMID 35485346, PMID 35605429, PMID 35695169, PMID 35870702, PMID 36089112, PMID 36201354, PMID 36509100, PMID 36927420, PMID 37353450, PMID 37524230, PMID 37791379, PMID 39119977, PMID 39389081
2017 (4), 2009 (3), 2014 (2), 2016 (2), 2019 (2), 2023 (2), 2015 (1), 2018 (1), 2025 (1), P01AI055793 (1), UM1CA186686 (1)